Total Payments
$4,078
2024 Payments
$1,814
Companies
5
Transactions
22
Payment Breakdown by Category
Research$3,089 (75.7%)
Travel$574.50 (14.1%)
Food & Beverage$338.58 (8.3%)
Education$76.00 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,089 | 13 | 75.7% |
| Travel and Lodging | $574.50 | 3 | 14.1% |
| Food and Beverage | $338.58 | 4 | 8.3% |
| Education | $76.00 | 2 | 1.9% |
Payments by Type
Research
$3,089
11 transactions
General
$989.08
9 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI PASTEUR INC. | $1,814 | 10 | $0 (2024) |
| Eli Lilly and Company | $1,396 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $791.84 | 5 | $0 (2017) |
| Genentech, Inc. | $76.00 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,814 | 10 | SANOFI PASTEUR INC. ($1,814) |
| 2019 | $76.00 | 3 | Genentech, Inc. ($76.00) |
| 2018 | $1,275 | 2 | Eli Lilly and Company ($1,275) |
| 2017 | $913.08 | 7 | Novartis Pharmaceuticals Corporation ($791.84) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $53.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $41.68 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $641.70 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $638.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $160.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $73.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $55.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $37.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/27/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $37.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 01/13/2019 | Genentech, Inc. | — | Education | In-kind items and services | $38.00 | General |
| 01/13/2019 | Genentech, Inc. | — | Education | In-kind items and services | $38.00 | General |
| 2019 | Digital Cognition Technologies, Inc. | — | — | — | $0.00 | Ownership |
| 01/09/2018 | Eli Lilly and Company | — | — | In-kind items and services | $1,274.79 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 2018 | Digital Cognition Technologies, Inc. | — | — | — | $0.00 | Ownership |
| 11/03/2017 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $70.00 | General |
| 11/02/2017 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.24 | General |
| 06/08/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $204.75 | General |
| 06/08/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $92.51 | General |
| 06/06/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $204.75 | General |
| 06/06/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $165.00 | General |
| 06/06/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $124.83 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | SANOFI PASTEUR INC. | $1,814 | 10 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,275 | 1 |
About Dr. Daniel Lawler, M.D
Dr. Daniel Lawler, M.D is a Anesthesiology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/31/2012. The National Provider Identifier (NPI) number assigned to this provider is 1356687958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Lawler, M.D has received a total of $4,078 in payments from pharmaceutical and medical device companies, with $1,814 received in 2024. These payments were reported across 22 transactions from 5 companies. The most common payment nature is "" ($3,089).
Ad
Practice Information
- Specialty Anesthesiology
- Location San Diego, CA
- Active Since 12/31/2012
- Last Updated 12/31/2012
- Taxonomy Code 207L00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356687958
Products in Payments
- CNP520 (Drug) $626.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anesthesiology Doctors in San Diego
Dr. Mark Wallace, Md, MD
Anesthesiology — Payments: $388,658
Anesthesiology $388,658
Alexander Roher, M.d, M.D
Anesthesiology — Payments: $273,497
Anesthesiology $273,497
Edward Obrien, Md, MD
Anesthesiology — Payments: $214,071
Anesthesiology $214,071
Dr. Gemayel Lee, M.d, M.D
Anesthesiology — Payments: $106,777
Anesthesiology $106,777
Dr. Daniel Lee, Md, MD
Anesthesiology — Payments: $94,291
Anesthesiology $94,291
Dr. Cory Gaconnet, M.d, M.D
Anesthesiology — Payments: $94,196
Anesthesiology $94,196